Azienda Sanitaria di Bolzano
Bolzano, 39100, Italy
Location status: Recruiting
Location contact
Marco Tomaino, Dr.
CONTACT
NCT Number: NCT06356207
Syncope is a common presenting condition. Pacemaker implantation can significantly reduce syncope recurrences in reflex syncope. However, despite careful selection, a substantial proportion of patients treated with pacemakers suffer recurrences of syncope. It is thought that a pronounced vasodepressor component may hinder the efficacy of pacing in patients, preventing adequate cerebral perfusion during the reflex, thus relativizing the anti-bradycardia function of the pacemaker to prevent syncope. It is hypothesised that the time elapsed from the actual loss of consciousness to the asystole recorded on the ECG during Tilt Table Test may be predictive in terms of response to pacemaker therapy, so this parameter becomes the subject of the present study.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Bolzano, 39100, Italy
Location status: Recruiting
Marco Tomaino, Dr.
CONTACT
Syncope is a common leading affection and is responsible for 1-3% of the presentations in emergency departments and up to 3% of inpatient admissions. Syncope poses often a diagnostic and therapeutic challenge for the attending physician and is often misdiagnosed or underdiagnosed. Patients can be treated with pacemaker implantation when the syncope cause is a cardioinhibition with documented asystole during the syncopal event. When accurately selected, patients benefit from pacemaker therapy with a significant reduction of syncope recurrence in the follow up. However, a substantial portion of the patients (approx. 25%) experience recurrence of syncope despite optimal pacemaker therapy. The underlying mechanism is not well understood and object of the current study.
The main target of the study is to evaluate the time elapsed between the T-LOC during Video Tilt Table Testing and the asystole at the ECG using a registry and to assess its predictive value in patients undergoing invasive treatment. The hypothesis is that a vasodepressive component could lessen the effect of pacing in a patient, leading to cerebral hypoperfusion and syncope despite maintaining a stable rhythm.
This is a prospective, multi-center observational study with 2 year follow-up of patients. Patients eligible for invasive treatment of reflex syncope are included.
If after guideline-directed implantable loop recorder insertion no cardioinhibition has been recorded, the patient is included automatically in the registry.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The main goal of the study is to evaluate the time elapsed between the T-LOC during Video Tilt Table Testing and the asystole at the ECG using a national registry and to assess its predictive value in patients undergoing invasive treatment. The hypothesis is that a vasodepressive component could lessen the effect of pacing in a patient, leading to cerebral hypoperfusion and syncope despite maintaining a stable rhythm.
Time frame: From enrollment to end of treatment 2 weeks
Time frame: From enrollment to treatment end 24 months
Time frame: 24 months
Contact information is provided by the study sponsor or research team.
Marco Tomaino, Dr.
CONTACT
Matthias Unterhuber, Dr. Dr.
CONTACT
Azienda Ospedaliera di Bolzano
Other
NeuroArrhythmias Area Registry of AIAC (NAARA) Syncope-Asystole Latency Time in Tilt Table Test (SALT-TILT) Study
Acronym: SALT-TILT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05621460
Autonomic Nervous System Diseases, Cardiovascular Diseases
Burnaby, British Columbia, Canada
View Trial DetailsNCT04755101
Autonomic Nervous System Diseases, Consciousness Disorders
Bonheiden, Belgium
View Trial DetailsNCT05755737
Autonomic Nervous System Diseases, Consciousness Disorders
Calgary, Alberta, Canada
View Trial DetailsNCT01548352
Arrhythmias, Cardiac, Autonomic Nervous System Diseases
Houston, Texas, United States
View Trial Details